Chemomab Therapeutics to Engage Investors in October Conferences
Chemomab Therapeutics Engaging Investors
Chemomab Therapeutics Ltd. (CMMB) is gearing up for two significant investor conferences where they will highlight their latest advancements. As a clinical-stage biotech company, Chemomab specializes in developing innovative therapies targeting fibro-inflammatory diseases that currently lack effective treatments.
Upcoming Investor Conferences
The management team at Chemomab will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference, taking place in New York City on October 9, 2024. This is a valuable opportunity for the company to communicate their vision and share insights into their product pipeline.
Details of the ROTH Conference
This invitation-only event will feature one-on-one meetings where investors can discuss the company's potential further. The format of the conference allows for personalized interactions, offering a platform for Chemomab’s leadership to articulate their strategic direction and growth plans.
Maxim Healthcare Virtual Summit
Following the ROTH conference, Chemomab’s co-founder and CEO, Dr. Adi Mor, will participate in a fireside chat during the Maxim Healthcare Virtual Summit scheduled for October 16, 2024. This session will provide insights into the company's clinical focus and the progress of their lead product.
Fireside Chat Insights
The Maxim summit will be accessible virtually, allowing a broader audience to engage with Dr. Mor's presentation. A recording of this chat will be available on Chemomab's investor relations website, ensuring that those who could not attend can still receive key information.
Introduction to Chemomab's Core Therapeutics
Chemomab is deeply committed to addressing severe fibro-inflammatory diseases with a notable unmet need. Their lead product, CM-101, is a promising therapeutic candidate that targets the protein CCL24, known for its role in fibrosis and inflammation. Early studies have shown that CM-101 not only maintains a favorable safety profile but also could potentially treat multiple severe conditions.
Advancements with CM-101
Recently, Chemomab reported encouraging results from its Phase 2 trial focusing on primary sclerosing cholangitis (PSC), a rare liver disorder. This has set the stage for pivotal milestones in 2025, including feedback from the FDA regarding the company’s plans for a Phase 3 registration trial. The company has achieved significant designations, such as Orphan Drug and Fast Track status, which bolster their development initiatives.
Future Prospects of Chemomab
Chemomab is not only focusing on PSC but is also preparing CM-101 for systemic sclerosis treatment, which has now reached Phase 2 readiness with an active IND in the U.S. This dual-path approach highlights the company’s versatility and dedication to addressing various fibro-inflammatory diseases.
Contact Information
For inquiries and more information, media representatives can contact Barbara Lindheim, the Consulting Vice President for Investor and Public Relations at Chemomab. She is reachable at +1 917-355-9234 or via email at barbara.lindheim@chemomab.com. Additionally, general investor-related questions can be directed to IR@chemomab.com.
Frequently Asked Questions
What is Chemomab Therapeutics known for?
Chemomab Therapeutics is a biotechnology company focused on developing therapeutics for fibro-inflammatory diseases.
When will Chemomab participate in investor conferences?
Chemomab will be attending investor conferences on October 9 and October 16, 2024.
Who is leading Chemomab's participation in the conferences?
Dr. Adi Mor, Chemomab's CEO, will notably participate in a fireside chat during the Maxim Healthcare Virtual Summit.
What is CM-101?
CM-101 is Chemomab's lead therapy targeting the protein CCL24 for treating fibro-inflammatory diseases.
How can investors stay updated on Chemomab's progress?
Investors can access presentations and recordings on Chemomab's investor relations website for updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- American Financial Group, Inc. Announces Quarterly Dividend Boost
- Exploring Growth in the Global Anti-Decubitus Cushions Market
- Dividend Increase Signals Strong Future for American Financial Group
- Exploring the Growth of Anti-Abrasion Foot Heel Stickers
- Innovative Career Solutions Drive EdTech Forward with AI
- Wade Chambers to Lead Engineering at Amplitude: A New Era
- Charles Taylor Welcomes Robert Paxton as New Canada Director
- Martin Marietta's Future: Challenges and Promising Prospects
- Union Pacific Stock Maintains Outperform Rating Amidst Changes
- Zip Launches Exciting Advertising Campaign Featuring Kelsey Plum
Recent Articles
- STP Launches Innovative BluePrint Platform for Investment Firms
- Jennifer Cable Joins J2 Ventures Advisory Board to Drive Innovation
- Marex Expands Global Reach with Dropet Biofuels Acquisition
- Simply Good Foods Prepares to Share Financial Results Soon
- Pebblebrook Hotel Trust Unveils 2024 Sustainability Achievements
- Legal-Bay Launches Informative Q&A Webpage for Plaintiffs
- Foghorn Therapeutics: Transforming Oncology at Upcoming Summit
- InspiroGene by McKesson: Revolutionizing Cell and Gene Therapies
- Valens Semiconductor Launches Advanced VA7000 and VS6320 Chipsets
- Canadian Solar's e-STORAGE Revolutionizes Energy in Chile
- Intertek Launches Innovative Global Compliance Service
- InMode Restructures Leadership for Strategic Growth Initiatives
- Revolutionizing Travel Safety: BOXX Insurance's Cyber Solution
- Dentalcorp: Celebrating Success as a Top Growing Company in Canada
- BOXX Insurance and World Travel Protection Launch Cyber Assist
- RedHill's Talicia® Secures Ongoing Access for Millions in California
- Meketa Investment Group Achieves Milestone Growth with New Team
- Sealed Air Welcomes Anthony Allott to Board of Directors
- Willis Lease Finance Corporation’s Major Preferred Stock Deal
- EmGenisys Wins $250,000 Grand Prize at BioTools Innovator
- FDA Fast Tracks Zilganersen for Treating Alexander Disease
- Colliers International Extends Leadership Contract with CEO
- Sara Egan Joins SignaPay as New Vice President of Sales
- Y-mAbs Therapeutics to Shine at Upcoming Investor Conferences
- Enbridge's Acquisition of PSNC Enhances U.S. Gas Utilities Growth
- Meta to Boost Virtual Reality Production in Vietnam by 2025
- Canadian Solar's e-STORAGE to Support Huatacondo Project Growth
- Pakistan's Inflation Rate Drops to New Low Amid Economic Reforms
- Apriori Bio Welcomes Harry Kleanthous as New CSO
- Akamai Technologies Plans Investor Call for Q3 Financials
- September Rally Lays Groundwork for SPX Gains Ahead
- Market Sentiment Shifts as US Indices Show Bullish Trends
- MRS Logística Chooses Iridium Certus for Enhanced Connectivity
- Garmin Launches Fusion Apollo Marine Audio Series for Boaters
- Silexion Therapeutics Advances SIL-204 for KRAS Cancer Treatment
- EDEN Highlighting Innovations at the Upcoming Service World Expo
- WESCO International Positioned for Growth Amid Positive Outlook
- Craneware Group Unveils Partnership with Microsoft Azure for Innovations
- Wolfe Research Updates Price Target for Vertex Pharmaceuticals
- ResMed's Growth Plans Highlighted At Recent Investor Event
- Driving Digital Transformation in Biopharma Manufacturing
- Onity Group: Strategic Moves Fuel Optimism Amid Restructuring
- GFL Environmental's Major Bond Offering and Growth Prospects
- Merck Acquires Promising Novel Antibody CN201 for Innovation
- CVS Explores Breakup: An In-Depth Look at Potential Changes
- IGM Biosciences: A Bright Outlook Amid Key Developments
- TD Cowen Adjusts Boeing Price Target While Keeping Buy Rating
- Concerns Mount as Israel Faces Credit Rating Challenges
- Kenya Faces Pressure to Address Corruption for IMF Aid
- Market Trends Anticipated as Labor Data Approaches